Eli Lilly and Company and Purdue University announced a strategic collaboration to conduct life science research. The five-year agreement, where Lilly will provide up to $52 million, marks Purdue’s largest strategic collaboration with a single company.
“Purdue has enjoyed a long history of engagement with Lilly. Now Lilly and Purdue University are entering into a new level of collaboration that will move us forward in areas core to both institutions,” said Purdue President Mitch Daniels. “Our investment on campus in the life sciences announced in 2016 is leading to just the types of impact we hoped to effect.”
The initial research focus areas include:
Developing improved delivery of injectable medicines with the goals of reducing pain, decreasing the number of injections, and enabling better patient compliance and overall health.
Developing predictive models for clinical success that reduce risks associated with investing in drug development and more effectively predict the outcome of new therapies in humans.
The collaboration envisions expansion to other areas to further utilize the range of expertise at the two institutions.
Purdue researchers from the natural and physical sciences, engineering and veterinary medicine will contribute to the interdisciplinary collaboration with Lilly researchers.